OpGen Announces Date of First Quarter 2019 Financial Results Conference Call
May 07 2019 - 6:30AM
OpGen, Inc. (NASDAQ: OPGN) announced today
that the Company will report its first quarter 2019 financial
results after the close of the U.S. financial markets
on Tuesday, May 14, 2019. OpGen’s management team will host a
live conference call and audio webcast at 4:30 p.m. Eastern
time to discuss the Company’s financial results and business
progress.
Dial-in Information U.S. Dial-In Number:
(844)-420-8185
International Dial-In Number:
(216)-562-0481
Conference ID: 6190299Webcast URL:
https://edge.media-server.com/m6/p/yxqz4fc4
Replay Dial-in Information U.S. Dial-In Number:
(855)-859-2056 International Dial-In Number: (404)-537-3406
Conference ID: 6190299
Following the conclusion of the conference call, a replay will
be available through May 28, 2019. The live, listen-only
webcast of the conference call may also be accessed by visiting the
investors section of the Company’s website
at www.ir.opgen.com. A replay of the webcast
will be available after the conclusion of the call and will be
archived on the Company’s website for 90 days.
About OpGenOpGen, Inc. is a precision medicine
company harnessing the power of molecular diagnostics and
informatics to help combat infectious disease. We are developing
molecular information products and services for global healthcare
settings, helping to guide clinicians with more rapid and
actionable information about life threatening infections, improve
patient outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs.
Our molecular diagnostics and informatics products, product
candidates and services combine our Acuitas molecular diagnostics
and Acuitas Lighthouse informatics platform for use with our
proprietary, curated MDRO knowledgebase. We are working to deliver
our products and services, some in development, to a global network
of customers and partners. The Acuitas AMR Gene Panel (RUO) is
intended for Research Use Only and is not for use in diagnostic
procedures. The Acuitas Lighthouse Software is not distributed
commercially for antibiotic resistance prediction and is not for
use in diagnostic procedures. For more information, please visit
www.opgen.com.
OpGen, Acuitas, and Acuitas Lighthouse are registered trademarks
of OpGen, Inc.
OpGen Contact: Michael Farmer Vice President,
Marketing (240) 813-1284 mfarmer@opgen.com
InvestorRelations@opgen.com
Press Contact: Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com
Investor Contacts: Joe Green Edison Group
jgreen@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2024 to Aug 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Aug 2023 to Aug 2024